April 2017
Two medications to be removed from the Medical Drug Prior Authorization Program
Beginning July 1, 2017, Delatestryl® (testosterone enanthate) and DepoDelatestryl®-Testosterone (testosterone cypionate) will be removed from the required Medical Drug Prior Authorization Program List.
Brand name |
HCPCS code |
DelatestrylDelatestryl® (testosterone enanthate) |
J3121 |
DepoDelatestryl®-testosterone (testosterone cypionate) |
J1071 |
Below are all the medications that are part of the Medical Drug Prior Authorization Program.
Drug name |
Drug name |
Drug name |
Drug name |
Actemra® |
Elaprase® |
Kalbitor® |
Ruconest® |
Acthar® gel |
Elelyso™ |
Kanuma™ |
Signifor® LAR |
Adagen® |
Entyvio™ |
Krystexxa® |
Simponi Aria® |
Aldurazyme® |
Exondys 51™ |
Lemtrada™ |
Soliris® |
Aralast NP™ |
Fabrazyme® |
Lumizyme® |
Spinraza™ |
Aveed® |
Firazyr® |
Makena® |
Stelara® |
Benlysta® |
Flebogamma® DIF |
Myobloc® |
Stelara IV® |
Berinert® |
Gammagard Liquid® |
Myozyme® |
Synagis® |
Bivigam™ |
Gammagard® S/D |
Naglazyme® |
Testopel® |
Botox® |
Gammaked® |
Nplate® |
Tysabri® |
Carimune® NF |
Gammaplex® |
Nucala® |
Vimizim™ |
Cerezyme® |
Gamunex® |
Octagam® |
Vpriv® |
Cimzia® |
Glassia™ |
Orencia® |
Xeomin® |
Cinqair® |
Hizentra® |
Privigen® |
Xgeva® |
Cinryze® |
HyQvia® |
Probuphine® |
Xiaflex® |
Cosentyx™ |
Ilaris® |
Prolastin®-C |
Xolair® |
Cuvitru® |
Immune globulin |
Prolia® |
Zemaira® |
Dysport® |
Inflectra™ |
Remicade® |
|
Note: The prior authorization requirement doesn’t apply to Federal Employee Program® members.
Blue Cross Blue Shield of Michigan reserves the right to change the prior authorization list at any time.
|